繁體
  • 简体中文
  • 繁體中文
×

熱門資訊> 正文

Galecto GAAP每股收益为-18.53美元，落后2.62美元

2025-03-20 04:52

  • Galecto press release (NASDAQ:GLTO): FY GAAP EPS of -$18.53 misses by $2.62.
  • Cash and cash equivalents as of December 31, 2024 were approximately $14.2 million. The Company anticipates that its cash and cash equivalents will be sufficient to fund operating expenses and capital requirements into 2026, including the submission of an investigational new drug application for GB3226 to the FDA. However, the Company will require substantial additional capital to finance its operations, including future clinical development of its GB3226 and GB1211 programs.

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
（工作日09：30 - 次日05：30）
客戶端：
關注我們：
  • 微信公眾號二維碼

© 2025 深圳市時代華盛網絡科技有限公司版權所有 粵ICP備16068286號